A randomized controlled trial comparing the efficacy of resveratrol combined with metformin versus resveratrol monotherapy in the management of polycystic ovary syndrome
Abstract
Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting women of reproductive age characterized by metabolic dysfunction, insulin resistance, and hormonal imbalance. Metformin, a well-known insulin sensitizer, and Resveratrol, an antioxidant polyphenol, have both shown promise in managing the metabolic and reproductive features of PCOS. This study evaluates the effects of Resveratrol alone and in combination with Metformin on clinical, metabolic, endocrine and reproductive parameters in women with PCOS over a 6-month period. A randomized controlled trial was conducted with PCOS women, who were assigned to two groups: one receiving Resveratrol monotherapy (33 participants) and the other receiving a combination of Resveratrol plus Metformin (30 participants). Treatment effects on demographic, anthropometric, clinical, endocrine and metabolic parameters were assessed at baseline, after 3 months and 6 months. Following dropouts and adverse effects, 25 participants were analyzed in each group for the final evaluation. statistical analysis was performed using SPSS version 26., employing t-tests, repeated measures ANOVA, and chi-square test. Where baseline imbalances existed, Analysis of Covariance (ANCOVA) was additionally performed to adjust for pre-treatment differences., with p < 0.05 considered significant. Both treatment groups showed significant within-group improvements over 6 months. Resveratrol monotherapy led to marked improvements in BMI, ovarian…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 33 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.